Media coverage about Petmed Express (NASDAQ:PETS) has trended positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petmed Express earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.4638214687092 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- PetMed Express, Inc. (PETS) Is Attracting Massive Concentrations By Volume Analysis (investingbizz.com)
- Amazon Teams Up With Monoprix, Bolsters Presence in Europe (finance.yahoo.com)
- Petmed Express (PETS) Rating Increased to Buy at ValuEngine (americanbankingnews.com)
- $67.84 Million in Sales Expected for Petmed Express Inc (PETS) This Quarter (americanbankingnews.com)
- Stock Inside Investors Spotlight: PetMed Express, Inc. (PETS) stock price is at $44.66 with movement of 0.77% – Nasdaq Express (nasdaqexpress.com)
PETS has been the topic of a number of analyst reports. BidaskClub upgraded Petmed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. Northcoast Research set a $58.00 price objective on Petmed Express and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine downgraded Petmed Express from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $42.80.
Petmed Express (NASDAQ:PETS) last announced its quarterly earnings data on Monday, January 22nd. The company reported $0.44 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.11. The firm had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 earnings per share. equities analysts predict that Petmed Express will post 1.77 EPS for the current fiscal year.
In other Petmed Express news, Director Ronald J. Korn sold 5,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the completion of the sale, the director now owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total value of $1,530,000.00. Following the sale, the chief executive officer now directly owns 490,000 shares of the company’s stock, valued at approximately $24,990,000. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,000 shares of company stock valued at $2,341,900. 4.00% of the stock is owned by insiders.
WARNING: This piece was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/03/29/petmed-express-pets-given-daily-coverage-optimism-score-of-0-27/1972480.html.
About Petmed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.